ENFN Quote, Financials, Valuation and Earnings

DigitalOcean Holdings has a net margin of 0.23% compared to Enfusion's net margin of 8.91%. Enfusion's return on equity of 3.17% beat DigitalOcean Holdings's return on equity of --.

Enfusion has a consensus price target of $11.25, signalling upside risk potential of 4.17%. On the other hand DigitalOcean Holdings has an analysts' consensus of $42.62 which suggests that it could grow by 52.96%. Given that DigitalOcean Holdings has higher upside potential than Enfusion, analysts believe DigitalOcean Holdings is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DigitalOcean Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DigitalOcean Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. DigitalOcean Holdings pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $52.9M, which are smaller than DigitalOcean Holdings quarterly revenues of $204.9M. Enfusion's net income of $121K is lower than DigitalOcean Holdings's net income of $18.3M. Notably, Enfusion's price-to-earnings ratio is 360.00x while DigitalOcean Holdings's PE ratio is 32.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.40x versus 3.41x for DigitalOcean Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Freshworks has a net margin of 0.23% compared to Enfusion's net margin of -11.26%. Enfusion's return on equity of 3.17% beat Freshworks's return on equity of -8.61%.

Enfusion has a consensus price target of $11.25, signalling upside risk potential of 4.17%. On the other hand Freshworks has an analysts' consensus of $20.18 which suggests that it could grow by 60.9%. Given that Freshworks has higher upside potential than Enfusion, analysts believe Freshworks is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Freshworks has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Freshworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. Freshworks pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $52.9M, which are smaller than Freshworks quarterly revenues of $194.6M. Enfusion's net income of $121K is higher than Freshworks's net income of -$21.9M. Notably, Enfusion's price-to-earnings ratio is 360.00x while Freshworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.40x versus 5.24x for Freshworks. Usually stocks with elevated PS ratios are considered overvalued.

Samsara has a net margin of 0.23% compared to Enfusion's net margin of -3.24%. Enfusion's return on equity of 3.17% beat Samsara's return on equity of -15.9%.

Enfusion has a consensus price target of $11.25, signalling upside risk potential of 4.17%. On the other hand Samsara has an analysts' consensus of $47.84 which suggests that it could grow by 23.14%. Given that Samsara has higher upside potential than Enfusion, analysts believe Samsara is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Samsara has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Samsara offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. Samsara pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $52.9M, which are smaller than Samsara quarterly revenues of $346.3M. Enfusion's net income of $121K is higher than Samsara's net income of -$11.2M. Notably, Enfusion's price-to-earnings ratio is 360.00x while Samsara's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.40x versus 17.30x for Samsara. Usually stocks with elevated PS ratios are considered overvalued.

Klaviyo has a net margin of 0.23% compared to Enfusion's net margin of -9.98%. Enfusion's return on equity of 3.17% beat Klaviyo's return on equity of -4.73%.

Enfusion has a consensus price target of $11.25, signalling upside risk potential of 4.17%. On the other hand Klaviyo has an analysts' consensus of $49.08 which suggests that it could grow by 89.13%. Given that Klaviyo has higher upside potential than Enfusion, analysts believe Klaviyo is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Klaviyo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Klaviyo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. Klaviyo pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $52.9M, which are smaller than Klaviyo quarterly revenues of $270.2M. Enfusion's net income of $121K is higher than Klaviyo's net income of -$27M. Notably, Enfusion's price-to-earnings ratio is 360.00x while Klaviyo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.40x versus 7.37x for Klaviyo. Usually stocks with elevated PS ratios are considered overvalued.